Cytokine Filtration in Lung Transplantation: A Swedish National Study (GLUSorb)

Recruiting N/A Interventional Study
Lung Transplant Failure Lung Transplant; Complications
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 80
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
116 (estimated)
Sponsor
Lund University Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Lung transplantation (LTx) remains the gold standard for treating patients with irreversible end-stage pulmonary disease. Of the major organs transplanted, survival in LTx recipients remains the lowest (mean 5 years). Despite improvements, primary graft dysfunction (PGD), as defined by respiratory insufficiency and edema up to 72 hours post LTx, remains the leading cause of early mortality and con…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: • Eligibility to undergo double lung transplantation at either trial site Exclusion Criteria: 1. Age \<18 years 2. Previous organ transplantation 3. Presence of any conditions at the time of surgery that require immunosuppressive therapy. Immunosuppressive therapy is defined a…
Contacts

Sandra Lindstedt, MD,PhD

+46737220580

sandra.lindstedt_ingemansson@med.lu.se

CONTACT

Jesper Magnusson, MD, PhD

jesper.magnusson@vgregion.se

CONTACT